Grey Wolf Therapeutics Closes Oversubscribed $50 Million Series B Financing Expansion, Led by ICG Life Sciences Team, to Accelerate and Expand First-of-its-Kind Antigen Modulation Technology

Brings Total Series B Funds Raised to Nearly $100 Million Proceeds to Support Broadening Scope of Ongoing Clinical Trial of GRWD5769; First Clinical Data to be Reported at ASCO 2024...
Read More

Promising preclinical data reported at AACR 2023

GWT reports promising preclinical data from research collaboration with Immunocore in oral presentation at the American Association for Cancer Research (AACR) Annual Meeting 2023...
Read More

Announcing the dosing of first patient in our clinical study

GWT announces dosing of first patient in phase 1/2 clinical study of GRWD5769 in patients with advanced solid tumours...
Read More

$49 Million Series B Financing Oversubscribed

Grey Wolf Therapeutics, a biotechnology company focused on generating entirely novel anti-tumour immune responses through targeted cancer neoantigen creation, today announced the closing of an oversubscribed $49 million Series B...
Read More

Supply agreement with Regeneron for GRWD5769 clinical trial

Grey Wolf Therapeutics Announces Clinical Supply Agreement with Regeneron for Trial Evaluating GRWD5769 in Combination with Libtayo® (cemiplimab) Combination of First-in-Class ERAP1 Inhibitor and Anti-PD-1 Monoclonal Antibody to be Studied...
Read More

Brett Carter joins board of Directors of Australian subsidiary

Grey Wolf Therapeutics, a biotechnology company generating entirely novel immune responses through targeted neoantigen creation, today announced the appointment of Brett Carter as a Non-Executive Director to the board of...
Read More